Laurus Labs, Krka to establish JV company in Hyderabad
It is expected that the necessary procedures and documentation for the registration of the new joint venture company will be finalised by the end of March 2024.
Hyderabad: Krka, an international generic pharmaceutical company in Novo Mesto, Slovenia and Laurus Labs have reached an agreement to establish a joint venture company Krka Pharma Pvt. Ltd. in Hyderabad, India.
Krka will hold 51% and Laurus 49% share in the joint venture. The registered capital of the newly founded company amounts up to Indian rupees equivalent to 50 million euros. The joint venture will enable the production of finished products for the new markets, including the Indian market.
Krka and Laurus have been working together contractually for many years and their businesses complement each other. The partners have discussed opportunities to strengthen co-operation and create synergies by combining their knowledge and resources.
Krka and Laurus have agreed to establish a joint venture company Krka Pharma Pvt. Ltd. with registered seat in Hyderabad, India. Krka will hold 51% and Laurus 49% share in the joint venture company. It is expected that the necessary procedures and documentation for the registration of the new joint venture company will be finalised by the end of March 2024. The parties have agreed on a step-by-step development of the joint venture company. The newly formed company will develop a plan to enter the Indian market and other markets outside the European Union where neither party is currently present with its finished products.
The registered capital of the newly established company amounts up to Indian rupees equivalent to 50 million euros. Krka and Laurus have agreed to subscribe to the registered capital in stages, depending on the financing needs of the gradual development of the joint venture’s business activities.
Commenting on this development, CEO of Laurus Labs Dr Satyanarayana Chava said, “Our business relationship with Krka is very matured over the years and growing year on year. This JV further cement our relationship to enhance product portfolio and markets. The JV also have plans to service quality products to India market over period of time”.
Read also: Laurus Labs, IIT Kanpur ink pact for novel gene therapy assets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.